Adverts

Open Access Articles- Top Results for Acorda Therapeutics

Acorda Therapeutics

Acorda Therapeutics Inc.
Public
Traded as NASDAQACOR FWBCDG
Industry Health care
Biotechnology
Founded 1995 (1995)[1]
Founder Ron Cohen
Headquarters Ardsley, New York, United States
Key people
Ron Cohen
Andrew R. Blight
Products Zanaflex
Ampyra
Qutenza
Revenue 11px US$292.2 Million (FY 2011)[2]
11px US$35.1 Million (FY 2011)[2]
#redirect Template:If affirmed 11px US$30.6 Million (FY 2011)[2]
Total assets 11px US$379.5 Million (FY 2011)[2]
Total equity 11px US$205.2 Million (FY 2011)[2]
Number of employees
328 (February, 2012) [2]
Website Acorda.com

Acorda Therapeutics is a biotechnology company based in Ardsley, New York, USA. The company develops drugs to improve therapies that improve neurological function in people with multiple sclerosis, spinal cord injury and other disorders of the central nervous system.[3] Acorda manufactures and markets the drugs Zanaflex, Ampyra and Qutenza in the United States.

History

Corporate governance

As of December 31, 2013, the members of the board of directors of Acorda Therapeutics were:[4] Ron Cohen, Barry Greene, Peder K. Jensen, John P. Kelley, Sandra Panem, Lorin J. Randall, Steven M. Rauscher, and Ian F. Smith.

Products

Products on the market

Products under development

References

External links


Lua error in package.lua at line 80: module 'Module:Buffer' not found. Lua error in package.lua at line 80: module 'Module:Buffer' not found.